

Brooks partners with Strides-backed SteriScience for global Carbapenems' business

Brooks and SteriScience will set up a front-end entity to market carbapenem products in the global markets:

- SteriScience will invest ₹100 million in the front-end entity for the regulatory filings.
- SteriScience will invest up to ₹400 million for creation of additional manufacturing facilities.

Mumbai, September 17, 2020:

In continuation of the Company's disclosure dated July 22, 2020, Brooks Laboratories Limited ("Brooks" or "Company") announced today that the process of formation of the marketing joint venture in partnership with SteriScience Private Limited ("SteriScience"), has been completed. The global marketing joint-venture arrangement, shall focus on international markets such as USA, Europe and other regulated markets. Simultaneously the joint venture partners have also entered into manufacturing joint venture towards building a robust carbapenem business with integrated manufacturing capabilities, **subject to approval from the shareholders of Brooks**. This is a landmark value-accretive partnership, which furthers Brooks' global aspirations.

Strides Pharma Science Limited ("Strides") is a majority shareholder of SteriScience. SteriScience, which is Strides' dedicated arm for sterile injectables, also marks the re-entry of Strides in injectables business, on completion of its non-compete period with Mylan Inc.

About the Joint venture with SteriScience

Brooks has entered into a JV with SteriScience to carry out manufacturing, marketing and distribution of carbapenems for the global markets through two joint venture entities. Carbapenems are a class of highly effective antibiotic agents commonly used for the treatment of severe or high-risk bacterial infections. It is a \$2 billion+ global opportunity with limited players having dedicated capabilities to manufacture these products. The partnership shall commercialize four products in the global markets along with the integrated infrastructure to manufacture both drug substance and drug product internally.

The broad terms of the JV transaction between SteriScience and Brooks are:

- a) Brooks and SteriScience will set up a front-end entity to market carbapenem products in the global markets, including the US, Europe, Canada, and Australia. This front-end entity will also own the IP/ANDAs/dossiers of all the carbapenem products across markets. The economic interest of Brooks will be **44.33%**. **Formation and capitalization of this entity has been completed.**
- b) SteriScience will invest ₹100 million in the front-end entity for the regulatory filings. The EU Filing for the first product was completed in August 2020.

- c) Subject to the approval from shareholders, Brooks shall transfer its EU approved manufacturing facility at Vadodara, India to a Joint Venture Company on a debt-free basis. Brooks will have 73.33% economic interest in this Joint Venture Company.
- d) Sterisience will invest up to ₹400 million in this facility to create additional capabilities including the manufacturing of all carbapenem APIs and also to commission a dedicated lyophilization line for Ertapenem.
- e) This manufacturing facility will be an exclusive partner to the front-end entity for the international markets.

Brooks' manufacturing expertise, coupled with SteriScience's domain proficiency, makes this partnership synergistic for unlocking and unearthing value in the global injectables' market.

About Brooks

Brooks Laboratories Limited, listed on the BSE Limited (533543) and National Stock Exchange of India Limited (BROOKS), is a pharmaceutical company headquartered in Mumbai, India. The Company mainly operates in both domestic and international markets. The Company's global manufacturing sites are located in India (Vadodara & Baddi). The Company focusses on "carbapenem" segment that are sold in over 100 countries. Additional information is available at the Company's website at www.brookslabs.net

For further information, please contact:

Brooks Investor Relations:

Jyoti Sancheti

Company Secretary

Email: investors@brookslabs.net